NEW YORK (TheStreet) -- AngioDynamics shares are up 0.4% to $19.27 in after-hours trading on Thursday following the release of the medical, surgical and diagnostic instruments manufacturer's second quarter financial results after the closing bell today. The company reported second quarter earnings that rose 21% over the previous year to 17 cents per diluted share, which topped analysts' expectations by 2 cents per share. Exclusive Report: Jim Cramer's Best Stocks for 2015 STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Revenue for the quarter increased by 4% to $92.1 million, beating analysts' guidance of $90.9 million in revenue during the period. Adjusted EBITDA for the quarter rose 18% over the previous year to $15.9 million. TheStreet Ratings team rates ANGIODYNAMICS INC as a Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation: "We rate ANGIODYNAMICS INC (ANGO) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall." Highlights from the analysis by TheStreet Ratings Team goes as follows: You can view the full analysis from the report here: ANGO Ratings Report ANGO data by YCharts STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Click to view a price quote on ANGO. Click to research the Health Services industry.
from Latest TSC Headlines http://ift.tt/1DqFAW7
No comments:
Post a Comment